AIMS: Gastrointestinal stromal tumours (GISTs) are commonly driven by oncogenic mutations in KIT and PDGFRA. However, 10-40% of these patients are wild-type for these genes. The prognostic significance of wild-type GISTs is controversial, and they rarely respond to imatinib. The aim of this study was to elucidate the molecular lesions underlying wild-type GISTs tumorigenesis. METHODS AND RESULTS: Twenty-nine KIT and PDGFRA wild-type GISTs were re-assessed for the presence of 'cryptic'KIT exon 11 duplications. Using a specific polymerase chain reaction assay, three previously undetected mutations were identified. In the remaining 26 wild-type GISTs, KIT, stem cell factor (SCF), phospho-KIT and phospho-ERK expression was evaluated by immunohistochemistry. Samples were screened for gain-of-function mutations in the mitogen-activated protein kinase (MAPK) cascade. KIT and SCF co-expression associated with KIT activation was observed in approximately 30% of cases. Furthermore, phospho-ERK expression showed that MAPK is activated in approximately 30% of cases. None of RAS family (H-, K- and N-RAS) oncogenes exhibited activating mutations, whereas BRAF mutations were found in approximately 4% of cases. CONCLUSIONS: In the absence of RAS mutations, MAPK could be activated through SCF/KIT autocrine/paracrine mechanisms and/or mutated BRAF in a subset of KIT/PDGFRA wild-type GISTs.
AIMS: Gastrointestinal stromal tumours (GISTs) are commonly driven by oncogenic mutations in KIT and PDGFRA. However, 10-40% of these patients are wild-type for these genes. The prognostic significance of wild-type GISTs is controversial, and they rarely respond to imatinib. The aim of this study was to elucidate the molecular lesions underlying wild-type GISTs tumorigenesis. METHODS AND RESULTS: Twenty-nine KIT and PDGFRA wild-type GISTs were re-assessed for the presence of 'cryptic'KIT exon 11 duplications. Using a specific polymerase chain reaction assay, three previously undetected mutations were identified. In the remaining 26 wild-type GISTs, KIT, stem cell factor (SCF), phospho-KIT and phospho-ERK expression was evaluated by immunohistochemistry. Samples were screened for gain-of-function mutations in the mitogen-activated protein kinase (MAPK) cascade. KIT and SCF co-expression associated with KIT activation was observed in approximately 30% of cases. Furthermore, phospho-ERK expression showed that MAPK is activated in approximately 30% of cases. None of RAS family (H-, K- and N-RAS) oncogenes exhibited activating mutations, whereas BRAF mutations were found in approximately 4% of cases. CONCLUSIONS: In the absence of RAS mutations, MAPK could be activated through SCF/KIT autocrine/paracrine mechanisms and/or mutated BRAF in a subset of KIT/PDGFRA wild-type GISTs.
Authors: Ricardo Celestino; Jorge Lima; Alexandra Faustino; Valdemar Máximo; António Gouveia; João Vinagre; Paula Soares; José Manuel Lopes Journal: Fam Cancer Date: 2012-06 Impact factor: 2.375
Authors: Céline Pinheiro; Vera Miranda-Gonçalves; Adhemar Longatto-Filho; Anna L S A Vicente; Gustavo N Berardinelli; Cristovam Scapulatempo-Neto; Ricardo F A Costa; Cristiano R Viana; Rui M Reis; Fátima Baltazar; Vinicius L Vazquez Journal: Cell Cycle Date: 2016-04-22 Impact factor: 4.534
Authors: Annick D Van den Abbeele; Constantine Gatsonis; Daniel J de Vries; Yulia Melenevsky; Agnieszka Szot-Barnes; Jeffrey T Yap; Andrew K Godwin; Lori Rink; Min Huang; Meridith Blevins; Jorean Sicks; Burton Eisenberg; Barry A Siegel Journal: J Nucl Med Date: 2012-03-01 Impact factor: 10.057
Authors: Filipe Pinto; Nathalia C Campanella; Lucas F Abrahão-Machado; Cristovam Scapulatempo-Neto; Antonio T de Oliveira; Maria J Brito; Raquel P Andrade; Denise P Guimarães; Rui M Reis Journal: Gastric Cancer Date: 2015-05-21 Impact factor: 7.370
Authors: Olga Martinho; António Gouveia; Paula Silva; Amadeu Pimenta; Rui Manuel Reis; José Manuel Lopes Journal: Virchows Arch Date: 2009-08-25 Impact factor: 4.064